Filing Flows › Caris Life Sciences (CAI) › Stock forecast & fair value
Caris Life Sciences (CAI) stock forecast and price target
Caris Life Sciences (CAI) trades at $25.23. 13 analysts' median price target is $35.00 (+39%), from $22.00 to $38.00.
Caris Life Sciences' latest quarter
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CAI stock?
The median of 13 analysts' 12-month targets is $35.00, +39% from $25.23; the range is $22.00 to $38.00. The average rating is buy.
Does Caris Life Sciences usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is CAI stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.